The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications by David, Owens
R E V I EW AR T I C L E
The continuing quest for better subcutaneously administered
prandial insulins: a review of recent developments and
potential clinical implications
David R. Owens MD1 | Geremia B. Bolli MD2
1Diabetes Research Group, Swansea
University Medical School, Wales, UK
2Department of Medicine, University of
Perugia Medical School, Perugia, Italy
Correspondence
David R. Owens MD, Diabetes Research
Group, Swansea University Medical School,
Singleton Park, Swansea SA2 8PP, UK.
Email: owensdr@cardiff.ac.uk
Funding information
Funding was provided by Sanofi for figure
preparation, article formatting and editing
Peer Review
The peer review history for this article is
available at https://publons.com/publon/10.
1111/dom.13963.
Abstract
The class of rapid-acting insulin analogues were introduced more than 20 years ago to
control postprandial plasma glucose (PPG) excursions better than unmodified regular
human insulin. Insulins, lispro, aspart and glulisine all achieved an earlier onset of action,
greater peak effect and shorter duration of action resulting in lower PPG levels and a
reduced risk of late postprandial hypoglycaemia. However, the subcutaneous absorption
rate of these analogues still fails to match the physiological profile of insulin in the sys-
temic circulation following a meal. Recent reformulations of aspart and lispro have gen-
erated a second generation of more rapid-acting insulin analogue candidates, including
fast-acting aspart (faster aspart), ultra-rapid lispro and BioChaperone Lispro. These modi-
fications have the potential to mimic physiological prandial insulin secretion better with
an even earlier onset of action with improved PPG control, shorter duration of effect
and reduced risk of hypoglycaemia. Recent phase 3 trials in type 1 and type 2 diabetes
show that faster aspart and ultra-rapid lispro compared with conventional aspart and
lispro, achieved fewer PPG excursions with a small increase in post-meal hypoglycaemia
but similar or marginally superior glycated haemoglobin levels, and suggest the need for
parallel optimization of basal insulin replacement. Phase 1 trials for BioChaperone Lispro
are equally encouraging with phase 3 trials yet to be initiated. Comparative analysis of
the clinical and pharmacological evidence for these new prandial insulin candidates in
the treatment of type 1 and type 2 diabetes is the main focus of this review.
K E YWORD S
clinical trials, hypoglycaemia, insulin therapy, pharmacodynamics, pharmacokinetics,
postprandial glucose, type 1 diabetes, type 2 diabetes
1 | INTRODUCTION
An essential component in diabetes management is to achieve and
maintain good glycaemic control in an attempt to reduce the risk of
micro- and macrovascular complications.1-3 Both fasting plasma
glucose and postprandial plasma glucose (PPG) contribute to overall
glycaemic control, as assessed clinically by the monitoring of gly-
cated haemoglobin (HbA1c) levels. The greater recognition of the
contribution of postprandial hyperglycaemia to elevated HbA1c
and consequent risk for diabetes complications highlights the
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importance of reducing PPG excursions,4 which remains a challeng-
ing aspect in clinical practice.5
The primary aim of subcutaneously administered mealtime-related
insulin formulations is to replicate the dynamics of endogenous prandial
insulin secretion, thereby controlling PPG excursions.6 In contrast to
unmodified regular human insulin (RHI), the current rapid-acting insulin
analogues (insulins lispro, aspart and glulisine), developed more than
20 years ago, through faster subcutaneous absorption, have an earlier
onset and shorter duration of action.7-9 These “first-generation” rapid-
acting insulin analogues, when compared with RHI in type 1 diabetes
(T1DM) in a multiple daily injection regimen, improve HbA1c by 0.15%10
and by 0.20%11 when delivered via subcutaneous insulin pumps. How-
ever, when rapid-acting analogues and basal insulin preparations are both
optimized, HbA1c decreases by more than 0.3% versus RHI,12,13 while
also decreasing the rate of hypoglycaemia.13
The enhanced absorption meant patient convenience was improved,
as administration of these analogues closer to, or at mealtimes became
possible.12,13 In current practice, to optimize PPG control the analogues
are recommended to be administered up to 20 min before meals or
within 20 min after starting a meal.5,14-16 Despite their enhanced subcu-
taneous absorption, the physiological mealtime insulin response is not
fully replicated, as the tissue barrier still delays insulin entry in blood with
consequent elevated PPG.9,17 Attempts to overcome PPG by increasing
the dose resulted in an increased risk of delayed inter-prandial
hypoglycaemia. Further improvements are required to simulate endoge-
nous mealtime insulin secretion better18 and alleviate the inconvenience
of anticipating meal timing, content and/or dosing requirements.5,14-16
Further adjustments have been made to the pharmaceutical formu-
lations of insulin to match normal prandial insulin secretion better, to
control meal-related glucose excursions without increasing the risk of
delayed hypoglycaemia.17,19,20 Initial attempts at a “second generation”
of rapid-acting insulin analogues involved the co-administration of
recombinant hyaluronidase enzyme (rHuPH20) to insulin lispro, aspart or
glulisine thereby disrupting the interstitial matrix of the subcutaneous tis-
sue and facilitating absorption.21,22 These analogues did not progress into
phase 3 clinical trials and the programme was discontinued. Subsequent
approaches included altering the excipients with several compounds
developed by Biodel (BIOD-100/123/238/250, Albireo Pharma Inc, Bos-
ton, Massachusetts); the first (BIO-100) involved adding
ethylenediaminetetraacetic acid and citrate to RHI,23 followed by BIOD-
12324 and BIOD-25025 with magnesium sulphate added to lispro, which
also reduced discomfort at the local injection site. These excipients acted
to destabilize the insulin hexamer enhancing its dissociation into dimers
and monomers.23 This programme has also been discontinued.26 How-
ever, the remaining members of the second generation of rapid-acting
insulin analogues that have or are due to enter phase 3 trials, namely
fast-acting aspart (hereafter called faster aspart), ultra-rapid lispro and
BioChaperone Lispro, are the main focus of this review, describing their
individual structure, mechanism of action and pharmacology, along with
evidence from their respective phase 1 and 3 clinical studies.
2 | SECOND GENERATION RAPID-ACTING
INSULIN ANALOGUES
2.1 | Structure and mechanism of action
The three candidates differ in terms of primary structure and mechanism
of faster absorption (Table 1). Faster aspart contains two additional
excipients, niacinamide and L-arginine. The niacinamide acts to increase
subcutaneous blood flow to enhance absorption while the amino acid L-
arginine serves as a stabilizing agent.27 Ultra-rapid lispro (LY900014) con-
tains the excipients citrate and treprostinil. The citrate enhances vascular
permeability at the injection site, while treprostinil accelerates lispro
absorption by increasing local vasodilation with no measurable systemic
exposure.28,29 BioChaperone Lispro contains the excipients citrate and
BioChaperone BC222.30 Citrate increases vascular permeability at the
injection site, while BioChaperone BC222 forms a physical complex with
insulin protecting it from enzymatic degradation while enhancing both its
stability and solubility increasing the rate of hexamer dissociation and
monomer absorption from the subcutaneous tissue.
2.2 | Pharmacokinetic/pharmacodynamic studies
The pharmacological properties for each of the second-generation
rapid-acting analogues have been characterized in a number of phase
1 trials.31-33 Most of these trials were single-dose studies comparing
each treatment with conventional aspart or lispro in subjects with
T1DM, administered by either subcutaneous injection or via continu-
ous subcutaneous insulin infusion (CSII). The majority of the faster
aspart trials have been published,34 while results of the trials for ultra-
TABLE 1 Current second-generation rapid-acting insulin analogues in development
Drug Company
Core insulin
structure Added excipients Mechanism of action
Faster aspart27 Novo Nordisk, Bagsværd,
Denmark
Insulin aspart Niacinamide (vitamin B3),
L-arginine
Increased subcutaneous blood flow
Ultra-rapid
lispro28,29
Eli Lilly, Indianapolis, IN Insulin lispro Treprostinil, citrate Enhanced vascular permeability and
increased local vasodilation
BioChaperone
Lispro30
Adocia, Lyon, France Insulin lispro BioChaperone BC222,a
citrate
Enhanced diffusion
aAn oligosaccharide modified with natural molecules.
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rapid lispro are currently only in abstract form.29,35-44 Two of the
BioChaperone Lispro trials have been published30,45 with several trials
reported as abstracts.46-51 Key findings from the completed trials are
summarized below.
2.2.1 | Features following subcutaneous injection
The pharmacokinetics of faster aspart (0.2 U/kg dose) were character-
ized in a pooled analysis of six studies in 218 adults with T1DM show-
ing that faster aspart was detected in the blood 5 min earlier than
aspart with onset of exposure (time to reach 50% of the maximum
concentration) 9.5 min earlier and an offset of exposure (time to late
half-maximum exposure) 12.2 min earlier (Table 2, Figure 1A).52 Initial
insulin exposure during the first 30 min after administration was two-
fold higher with faster aspart. Three 12-h euglycaemic clamp trials
characterized the pharmacodynamics of faster aspart.52 Similar to the
pharmacokinetic profile, early glucose-lowering, as measured by the
glucose infusion rate (GIR) during the first 30 min was 74% greater for
faster aspart (Figure 2A). In meal tests in persons with T1DM, faster
aspart (0.2 U/kg) improved PPG when given immediately before a
liquid meal (Figure 3A); mean reductions versus aspart during the first
2 h were in the range of 10–26 mg/dL (0.6–1.4 mmol/L) in adults and
4–27 mg/dL (0.2–1.5 mmol/L) in children/adolescents.53,54
The pharmacological features of ultra-rapid lispro were character-
ized in a single-dose study in 36 people with T1DM showing that
ultra-rapid lispro was detected in the blood 8.8 min earlier (15.5
vs. 24.3 min) than lispro (Table 2) with a twofold higher insulin expo-
sure over the first 30 min (Figure 1B).36 Ultra-rapid lispro also showed
a greater early glucose-lowering effect, as measured by GIR, when
compared with lispro (Figure 2B). In meal tests, ultra-rapid lispro
improved PPG control when given immediately before a mixed meal
(composition not reported) in persons with either T1DM36,37,40 or
type 2 diabetes (T2DM).39 Glucose excursions with ultra-rapid lispro
were lower by 39%–47% during the first 2 h after the start of this
(presumably liquid) meal (Figure 3B).37,39 In a further multiple compar-
ison study in 68 people with T1DM, time to onset of ultra-rapid lispro
exposure occurred earlier than with faster aspart, lispro and aspart
(Table 2).43 Initial insulin exposure during the first 30 min after admin-
istration of ultra-rapid lispro was also higher than faster aspart
(1.2-fold), lispro (2.9-fold) and aspart (2.4-fold). Offset of exposure
occurred earlier than with the other analogues. PPG excursions
TABLE 2 Key pharmacokinetic and pharmacodynamic results of second-generation rapid-acting insulins versus comparators in subjects
with T1DM
Comparator Administration
Faster
aspart Ultra-rapid lispro BioChaperone Lispro
Aspart Lispro Aspart
Faster
aspart Lispro Aspart
Faster
aspart
Pharmacokinetics
Onset (tEarly50%Cmax) sc injection −9.5 min52 −8.836 to
−12.543 min
−13.9 min43 −5.9 min43 −10.7 mina48 NR NR
CSII −11.8 min55 −8.6 min40 NR NR NR −11.7 min30 −0.7 min30
Offset (tLate50%Cmax) sc injection −12.2 min52 −7.036 to
−13.843 min
−21.1 min43 −9.5 min43 −28.2 mina48 NR NR
CSII −35.4 min55 −12.2 min40 NR NR NR NR NR
Early exposure
(AUC30 min)
sc injection "~2-fold52 "~2.236- to 2.943-
fold
"2.4-fold43 "1.2-fold43 "2.5a48- to 2.749-
fold
NR NR
CSII "~3-fold55 "1.5-fold40 NR NR NR NR NR
Pharmacodynamic
Onset (tEarly50%GIRmax) sc injection −9.5 min52 −12.2 minb35 NR NR −10.0 min47 NR NR
CSII −11.1 min55 NR NR NR NR −13.0 min30 +1.3 min30
Offset (tLate50%GIRmax) sc injection −14.3 min52 0 minb35 NR NR NR NR NR
CSII −24.0 min55 NR NR NR NR −38.2 min30 −19.6 min30
Early effect
(AUCGIR,30 min)
sc injection "~1.7-fold52 NR NR NR ">3-fold47 NR NR
CSII "~2-fold55 NR NR NR NR NR NR
Table shows mean time difference versus comparators. Items in bold are statistically significant. Table adapted from oral presentation by Tim Heise at
American Diabetes Association Symposium on June 25, 2018.
Abbreviations: AUC, area under the insulin concentration curve; CSII, continuous subcutaneous insulin infusion; GIR, glucose infusion rate; NR, not
reported; sc, subcutaneous; tEarly50%Cmax, time to 50% of maximum insulin concentration in the early part of the pharmacokinetic profile; tLate50%Cmax, time
to late half-maximum insulin exposure; T1DM, type 1 diabetes.
aMean data from two studies in patients with T1DM.48
bIn healthy subjects.
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following a liquid meal test (100 g of carbohydrate) were numerically
lower with ultra-rapid lispro than faster aspart and significantly lower
versus lispro and aspart.
The pharmacokinetics of BioChaperone Lispro (0.2 U/kg) were
characterized in a pooled analysis of two studies in 76 adults with
T1DM showing that BioChaperone Lispro was detected in the blood
11 min earlier than lispro (Figure 1C) with offset of exposure occur-
ring 28.2 min earlier (Table 2).48 Initial insulin exposure during the first
30 min after administration was more than twofold higher with
BioChaperone.48 BioChaperone Lispro showed a greater glucose-
lowering effect, as measured by GIR, within the first hour compared
with lispro (Figure 2C).47 In standardized liquid (80 g carbohydrate) or
individualized solid (50% carbohydrate) meal tests in persons with
T1DM45,49 or T2DM,50 BioChaperone Lispro reduced glucose
excursions by 22%–61% during the first 2 h compared with lispro
(Figure 3C).
2.2.2 | Features when used in continuous
subcutaneous insulin infusion (pumps)
When faster aspart was given via CSII as a bolus of 0.15 U/kg on top of a
basal rate of 0.02 U/kg/h, plasma insulin levels were threefold higher than
aspart during the first 30 min.55 Onset of exposure occurred 11.8 min ear-
lier (20.7 vs. 32.5 min) with faster aspart and the glucose-lowering effect
during the first 30 min was increased by more than 100%.
When ultra-rapid lispro was given via CSII (bolus dose 15 U, basal
dose not reported), insulin exposure [area under the insulin
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concentration curve (AUC)] was more than 50% higher than lispro
during the first 15 min and the onset of exposure occurred 8.6 min
earlier (15.6 vs. 24.1 min) (Table 2).40
When BioChaperone Lispro was given via CSII (0.15 U/kg bolus
on top of basal rate 0.01 U/kg/h), early insulin exposure (AUC) during
the first hour was more than 60% higher than aspart, with offset of
exposure occurring 38.2 min earlier (Table 2).30 In the same study,
early insulin exposure during the first hour was 14% higher than faster
aspart with offset of exposure occurring 19.6 min earlier.
In summary, despite differences in the structure and mechanism of
action, the pharmacokinetic profiles of the three candidates are quite
similar (Table 2), demonstrating an earlier and higher peak concentra-
tion with a shorter duration of action relative to their predecessors
(Figure 1). The differences in onset of action range from 9 to 14 min
with an offset of effect in the range of 7–28 min with respect to their
half-maximal metabolic effects (Table 2).56 This degree of difference is
qualitatively similar to that seen previously between the current con-
ventional rapid-acting insulin analogues and RHI. However, none has
been compared against insulin glulisine, which has been shown to have
a slightly faster onset of action than both aspart and lispro.57-60
2.3 | Phase 3 clinical trials
Eight phase 3 trials have reported the efficacy and safety of faster
aspart (Table 3A).61-70 Seven phase 3 trials are evaluating the efficacy
and safety of ultra-rapid lispro versus lispro,71-77 with preliminary
results for three of these trials reported as abstracts.71,74,76,78 The
phase 3 trial programme for BioChaperone Lispro is yet to be
announced.
2.3.1 | Trials in adults with type 1 diabetes
Two similarly designed studies compared mealtime faster aspart
(administered 0–2 min before a meal) with mealtime aspart in a basal-
bolus regimen in a 52-week trial with insulin detemir (Onset 1) and in
a 26-week trial with insulin degludec (Onset 8).61-64 In Onset 1, HbA1c
was reduced with faster aspart versus aspart by 0.15% after week
2661 and by 0.10% at week 52.62 No significant difference in HbA1c
was observed in Onset 8 [estimated treatment difference (ETD) of
−0.02% in favour of faster aspart].63 The rate of severe or blood glu-
cose (BG)-confirmed hypoglycaemia was comparable in both trials.
PPG increment at 1-h post-meal in a liquid meal test was reduced
with faster aspart versus aspart in both trials at week 26,61,63 and at
week 52 in Onset 1 (see Table 3A for details).62 When faster aspart
was administered within 20 min after meal initiation PPG increment
at 1-h post-meal in a meal test was higher versus mealtime aspart in
both trials.61,63 Mean PPG levels based on the results of self-monitored
plasma glucose (SMPG) profiles with consumption of solid mixed meals,
were reduced with faster aspart across all meals in both trials.62,63 In
the 26-week Onset 8 trial, the self-measured PPG increment at 1 h
was also reduced for faster aspart but there was a trend for higher
levels at bedtime.63 Hypoglycaemia within the first hour from meal ini-
tiation was increased with faster aspart in Onset 1 at 26 and
52 weeks,61,62 while in Onset 8, a reduced rate of hypoglycaemia
3–4 h after meal initiation was seen with faster aspart.63 The cause of
the discrepancy between these two studies is not apparent, although
the use of different basal insulins may play a role.
A single trial (PRONTO-T1D) compared mealtime ultra-rapid
lispro (administered 0–2 min before a meal) with lispro in a basal-bolus
treatment regimen (Table 3B).71,78 The change from baseline in HbA1c
after 26 weeks was similar with both treatments (ETD −0.08%,
P = 0.06). Administration of ultra-rapid lispro 20 min after the start of
a meal was less effective (but still non-inferior) than pre-meal lispro
(HbA1c ETD +0.13%, P = 0.003). PPG increment at 1 and 2 h post-
meal in a liquid meal test at week 26 (see Table 3B for details) was
reduced with ultra-rapid lispro. Similarly, PPG increment at 1 h based
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on SMPG was reduced with ultra-rapid lispro at breakfast, with no
difference at midday or following the evening meal. Severe, over-
all and early (≤4 h) postprandial BG-documented hypoglycaemia
was similar between treatments with fewer episodes observed
with mealtime ultra-rapid lispro in the late (>4 h) postprandial
period.
2.3.2 | Trials in children and young persons with
type 1 diabetes
A single trial (Onset 7) in children and young persons (1–17 years)
compared faster aspart with aspart in a basal-bolus regimen.65 HbA1c
was reduced with faster aspart versus aspart by 0.17% at week
26 with a comparable rate of severe or BG-confirmed hypoglycaemia.
PPG increment at 1 h based on the SMPG profile was reduced with
faster aspart at breakfast, dinner and across all meals (0.93 mmol/L
improvement). Administration of post-meal faster aspart was less
effective (but still non-inferior) than aspart with the 1-h PPG incre-
ment from SMPG across all meals also slightly worse than aspart
(+0.43 mmol/L). No studies are available with ultra-rapid lispro or
BioChaperone Lispro.
2.3.3 | Trials in type 2 diabetes
Two studies compared mealtime faster aspart with aspart in a basal-
bolus regimen in a 26-week trial with insulin glargine 100 U/mL
(glargine-100) (Onset 2)66 and in a 16-week trial with insulin degludec
(Onset 9).70 No significant difference in HbA1c at the end of treat-
ment was observed in either trial (ETD −0.02% in Onset 2, −0.04% in
Onset 9; both in favour of faster aspart). The rate of severe or BG-
confirmed hypoglycaemia was comparable in the 26-week trial, but
significantly lower for faster aspart in the 16-week trial. PPG incre-
ment at 1 h post-meal in liquid meal tests at the end of each trial was
reduced with faster aspart. However, PPG across all daily meals based
on the SMPG was comparable in the 26-week trial but significantly
lower in the 16-week trial (along with a reduced 1-h PPG increment
after lunch and the evening meal) for faster aspart. The improved PPG
control in the 16-week trial was counter-balanced by an increase in
early (0–2 h) post-meal hypoglycaemia.
A further 18-week trial evaluated the addition of faster aspart
versus placebo to basal insulin and metformin (Onset 3).67 As
expected, a significant improvement in HbA1c (ETD −0.94%) and self-
monitored 2-h PPG across all meals was seen with the basal-bolus
using faster aspart versus basal insulin only.
A single trial (PRONTO-T2D) has compared mealtime ultra-rapid
lispro with lispro in a basal-bolus regimen (Table 3B).76 HbA1c was
reduced with both treatments by a similar amount after 26 weeks
(ETD +0.06%) with a comparable rate of severe or BG-confirmed
hypoglycaemia. PPG increment at 1 and 2 h post-meal in a liquid meal
test at week 26 was reduced with ultra-rapid lispro, with the benefits
extending out to 4 h. PPG increment at 1 and 2 h and daily mean PPG
levels/excursions based on the SMPG profile were reduced with
ultra-rapid lispro.79
2.3.4 | Trials in pumps and closed-loop systems
Two trials (Onset 4 and 5) evaluated the use of faster aspart versus
aspart when delivered via CSII pumps. Pump compatibility of faster
aspart over 6 weeks in terms of the risk of catheter occlusions was
TABLE 3B Key features and results of reported phase 3 trials
comparing mealtime ultra-rapid lispro with mealtime lispro
Parameter
T1DM basal-bolus T2DM basal-bolus
PRONTO-T1D71,78
PRONTO-
T2D76,79
Comparator Mealtime lispro Mealtime lispro
Basal insulin used Gla-100/IDeg Gla-100/IDeg
Participants (n) 451 vs. 442 336 vs. 337
Duration (weeks) 26 (52) 26
Glycaemic control
Δ HbA1c (%) −0.08 +0.06
Meal testa
Composition Liquida, ~100 g
CHO (~57%
kcal)
Liquida
Consumption time NR NR
ΔPPG1-h, mmol/L −1.55 −0.66
ΔPPG2-h, mmol/L −1.73 −0.96
ΔPPG3-h, mmol/L NR (P < 0.001) NR (P < 0.001)
ΔPPG4-h, mmol/L NR (P < 0.05) NR (P < 0.05)
Hypoglycaemia rateb
Documented, RR 0.92 1.02
Post-meal ≤1 h, RR 1.16 1.14
Post-meal ≤2 h, RR 1.11 1.33
Post-meal >1 to ≤2 h,
RR
1.07 2.31
Post-meal >2 to ≤4 h,
RR
1.01 1.44
Post-meal ≤4 h, RR 1.06 NR
Post-meal >4 h, RR 0.62 (P < 0.001) 0.95
Table shows mean difference versus mealtime lispro. Confidence intervals
around point estimates are not shown for simplicity. Items in bold are
statistically significant.
Abbreviations: Δ, change; lispro, insulin lispro; ΔHbA1c, ETD in mean
HbA1c Δ from baseline (%); ΔPPG1-h, ETD in 1-h PPG increment; IDeg,
insulin degludec; ETD, estimated treatment difference; Gla-100, insulin
glargine 100 U/mL; NR, not reported; PPG, postprandial glucose; RR,
relative rate; SH, severe hypoglycaemia; SMPG, self-monitored plasma
glucose; T1DM, type 1 diabetes; T2DM, type 2 diabetes.
aStandardized liquid mixed meal tolerance test (MMTT).
bHypoglycaemia defined as blood glucose documented [<3.0 mmol/L
(54 mg/dL)] events with or without symptoms.
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investigated in 37 persons with T1DM.68 Although there was a trend
towards better glycaemic control with faster aspart and a similar risk of
hypoglycaemia, unexplained hyperglycaemia and premature infusion
set changes (<72 h) were more common. There were 21 premature
infusion-set changes in 11 (44%) of the faster aspart users compared
with four in two (17%) of the aspart users.80 Only one-third of those in
the faster aspart group could be attributed to purely technical issues
(e.g. empty reservoir, kinked or dislodged infusion-set tubing) compared
with three-quarters explainable in aspart users. No confirmed cases of
microscopic occlusions of the infusion sets (Quick-Set® or Silhouette®
[Medtronic, Northridge, CA]) were seen when faster aspart (25 persons)
or aspart (12 persons) were used in connection with a MiniMed Para-
digm® (Medtronic, Northridge, California) pump.
In the larger Onset 5 trial, the change from baseline in HbA1c
after 16 weeks was slightly in favour of aspart (ETD 0.09%, P < 0.02)
with a comparable rate of severe or overall BG-confirmed
hypoglycaemia.69 PPG increment at 1 and 2 h post-meal in a liquid
meal test at 16 weeks was reduced with faster aspart. Changes from
baseline in 1- and 2-h interstitial glucose (IG) increments assessed by
continuous glucose monitoring were also significantly lower with
faster aspart across all meals. However, the proportion of IG values in
the target range of 4–10 mmol/L (71–180 mg/dL) was the same in
each treatment group. Nocturnal, pre-meal and 4 h post-meal (particu-
larly the evening meal) IG levels were higher with faster aspart. It was
postulated that the elevated nocturnal IG levels with faster aspart
might have been because of suboptimal pump settings for the evening
meal bolus, lack of basal insulin compensation because of the shorter
bolus insulin action, or suboptimal basal insulin rates at night.81
Hypoglycaemia within the first hour from meal initiation was
increased with faster aspart. Similar to Onset 4, a higher number of
participants on faster aspart experienced events related to infusion-
site reactions versus aspart {5.5% of participants [0.29 events/
patient-years of exposure (PYE)] vs. 3.8% of participants (0.18 events/
PYE), respectively}. In addition, a greater number of participants
required non-regular change of the infusion set [45.8% of participants
(2.76 events/PYE) vs. 31.8% of participants (2.87 events/PYE),
respectively].
Two small trials have reported on the use of faster aspart in
closed-loop delivery systems. The first trial in 20 participants with
T1DM showed a similar proportion of time in target range (primary
endpoint) versus aspart.82 A further study in 15 adults with T2DM
showed that faster aspart achieved comparable glucose control (time
in target range) vs aspart although a higher dose of faster aspart was
required to achieve this outcome.83
Two trials (PRONTO-Pump and PRONTO-Pump 2) are evaluating
ultra-rapid lispro use via CSII pumps.74,75 Pump compatibility of ultra-
rapid lispro versus lispro over 6 weeks in terms of the rate of infusion
set failures (premature infusion set changes because of a pump occlu-
sion alarm or unexplained hyperglycaemia) was investigated in 49 per-
sons with T1DM (PRONTO-Pump).74 Although there was no
difference in the rate of infusion set failures between the two treat-
ments, premature infusion set changes (≤72 h) were more common
with the use of ultra-rapid lispro. There were 77 premature infusion-
set changes in ultra-rapid lispro users versus 52 in lispro users (aggre-
gate rate: 1.13 vs. 0.78 events per 30 days, P = 0.028). A trend
towards better glycaemic control with ultra-rapid lispro during the
6 weeks was observed with no difference in the risk of
hypoglycaemia. The results of the PRONTO-Pump 2 study are not yet
available.75
2.4 | Regulatory status
Faster aspart was approved in 2017 in Europe and the USA for use in
adults with diabetes,84,85 and subsequently in both regions for use in
children or adolescents aged ≥1 year. Prescribing guidelines recom-
mend faster aspart should be given immediately before a meal,
although it may be given up to 20 min after starting a meal if neces-
sary.85,86 Faster aspart is also approved in Europe and the USA for
CSII by external delivery systems.85,86 Regulatory applications for
ultra-rapid lispro have been submitted in Europe and Japan, and were
intended in the USA in late 2019.87
3 | WHAT IS THE POTENTIAL ROLE FOR
THE SECOND-GENERATION OF
RAPID-ACTING INSULINS?
Faster aspart is the first and most extensively investigated of the
three newer rapid-acting insulins and the only one currently approved
for clinical use. Trials in patients with T1DM show a significant
improvement in PPG increment at 1 h (mean decrease −0.90 to
−1.18 mmol/L) compared with aspart.61,63,69 The limitation of the liq-
uid meal tests in these trials should be noted as in real-life, solid mixed
meals are more commonly consumed with a slower and more pro-
longed absorption period. The observed improvement in the 1 to 2-h
PPG increment is sometimes offset by a slightly higher 4-h PPG
(Onset 5), suggesting a need for optimizing the basal insulin and/or
adjusting the prandial insulin during an extended inter-prandial period.
This is conceptually similar to what was observed more than 20 years
ago with the introduction of rapid-insulin analogues.13,88 Trials in peo-
ple with T2DM show a similar but lesser, yet statistically significant,
reduction in the 1-h PPG increment (mean decrease −0.40 to
−0.59 mmol/L) compared with aspart.66,70 Despite reducing PPG
levels in the trials reported, the overall glucose-lowering ability of
faster aspart compared with aspart (based on HbA1c levels) was com-
parable in T2DM66,70 or slightly better in T1DM.61-63,65 SMPG profile
data in several trials indicate that faster aspart has a minimal effect on
reducing PPG after mixed meals. It could be that the duration of
increased bioavailability in the early phase of their absorption is too
short with mixed meals thereby exposing patients to late postprandial
hyperglycaemia 3–4 h after meals. Several studies observed a slight
increase in hypoglycaemia within the first 1–2 h following pre-meal
faster aspart,61,62,66,69 although other studies showed no difference in
the risk. In this regard, the possible risk of early hypoglycaemia in indi-
vidual patients should be considered in relation to meal composition,
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thereby placing the patient at the centre of controlling postprandial
glycaemic excursions with glucose monitoring.16
Preliminary data for ultra-rapid lispro from two phase 3 trials
have recently been presented. In people with T1DM, ultra-rapid
lispro improved PPG increment at 1 h (mean decrease
−1.55 mmol/L) in a liquid meal test compared with lispro. Similarly,
in persons with T2DM, a lesser, although significant, improvement
in the 1-h PPG increment (−0.66 mmol/L) was observed. In both tri-
als, PPG excursions with ultra-rapid lispro were significantly lower
within 30 min and persisted for up to 4 h after the test meal.
Despite reducing PPG levels, HbA1c levels were comparable with
lispro in both populations. Safety data reported to date do not indi-
cate an increase in postprandial hypoglycaemia risk compared with
lispro. The limited data currently presented preclude comparison
with the data for faster aspart.
Each of the phase 3 clinical studies comparing faster aspart or
ultra-rapid lispro with aspart/lispro have generally given each drug
just before the meal (0–2 min), although some studies had a third
group with the faster-acting analogues given post-meal. No study has
compared the current rapid-acting insulins (aspart/lispro/glulisine)
given 15–20 min before the meal with the new faster-acting analogue
given at the time of the meal (0–2 min). In this situation, the faster-
acting analogue might not demonstrate superior 1 and 2-h PPG con-
trol. Similarly, it is not known whether the risk of hypoglycaemia with
aspart/lispro/glulisine given 15–20 min before the meal is similar or
lower than the faster-acting analogues given with a meal.
CSII is an increasingly popular and effective method of subcuta-
neous insulin administration.56 Insulins with a faster onset and off-
set of glucose-lowering effect are particularly attractive in a CSII
setting to improve PPG control further while limiting the risk of late
post-meal hypoglycaemia.89 However, the results of the two clinical
trials of faster aspart appear to suggest that this analogue is less
stable and has a higher occlusion rate of CSII catheters than aspart.
The cause of this lower physico-chemical stability is currently being
explored and in view of the uncertainty about a more frequent need
to replace the infusion sets and a lack of practical guidance on the
optimal use of faster aspart,81 the current rapid-acting insulin thera-
pies could probably remain the preferred analogues for use in CSII.
Limited data have so far been presented for ultra-rapid lispro.74
Neither insulin has been evaluated in children or young persons
with diabetes. The potential that these new rapid-acting insulins
could improve the performance of closed-loop automated insulin
delivery systems (e.g. the artificial pancreas) remains of great
interest,90 with ongoing trials evaluating their use in this
environment.
4 | CONCLUSIONS
The new second-generation of rapid-acting insulin analogues
described in this review have applied different modifications in phar-
maceutical formulation to enhance further the rate of subcutaneous
absorption of the insulin, which is an attempt to achieve better control
of PPG when compared with their predecessors. This has been suc-
cessfully achieved. However, there is only a minimal improvement in
overall glycaemic control (HbA1c), and no lesser risk of inter-prandial
hypoglycaemia as observed in a limited number of long-term studies in
persons with T1DM and T2DM. To achieve optimal glycaemic control,
individualized adjustments of basal insulin (subcutaneous bolus or CSII)
and/or additional small boluses of the faster-acting insulin analogue
may also be required to accommodate prolonged inter- or postprandial
periods. Because the majority of trials evaluating PPG excursions have
used liquid meals, additional information is required for solid meals
with different compositions mimicking real-life conditions.
Future studies are needed to answer the question as to which
patients would benefit most from these new insulin analogues, as
compared with those who would not. At present, it is tempting to
speculate that the newer rapid-acting insulin analogues would be
of particular value for individuals with marked post-breakfast
hyperglycaemia, because of the dawn phenomenon91 and/or insu-
lin resistance, individuals on corticosteroids, fertile women in the
second half of the menstrual cycle and those individuals who regu-
larly or intermittently consume meals with a high content of
refined carbohydrates. On the other hand, there are limited data
available on the benefit of these new insulins in people experienc-
ing delayed gastric emptying who may be at greater risk of
hypoglycaemia soon after their meals. In addition, it is also impor-
tant to recognize the possible need to optimize basal insulin sup-
plementation, when introducing these newer prandial insulins.
Therefore, future trials should clarify their role in various clinical
scenarios typically encountered in daily clinical practice. Their
application in CSII devices also remains at an early phase with
compatibility issues to be clarified.
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